Bristol's Belatacept Gets Wary Green Light From FDA Advisory Panel
The company proposed a REMS in advance for the kidney transplant drug, and post-market safety monitoring is indeed essential, committee members said.
The company proposed a REMS in advance for the kidney transplant drug, and post-market safety monitoring is indeed essential, committee members said.